Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 28, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 ordinary shares of 25 pence each.
- Purchase Price: 1,462.82 pence per share.
- Total Treasury Shares Held: 176,601,678 shares following the transaction.
- Shares in Issue: 5,807,442,935 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 500,000 shares on June 28, 2006, which are now held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase based on the disclosed price of 1,462.82 pence per share.
- Confirm the updated share capital structure: 5,807,442,935 shares in issue and 176,601,678 shares held in Treasury.
- Note that this filing is a notification of a specific transaction and does not contain periodic financial performance data.